Literature DB >> 31345844

Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for FKS-Associated Echinocandin Resistance in Candida glabrata Septic Arthritis and Osteomyelitis.

William F Wright1, Nika Bejou2, Ryan K Shields3, Kieren Marr4, Todd P McCarty5, Peter G Pappas6.   

Abstract

We report the case of a 61-year-old female with Crohn's disease dependent on total parenteral nutrition who developed a central venous catheter bloodstream infection and septic arthritis, complicated further by osteomyelitis and persistent Candida glabrata fungemia. Fluconazole treatment led to persistent infection, and micafungin therapy failed with development of FKS-associated resistance. Infection responded after initiation of amphotericin B plus voriconazole. Echinocandin resistance is increasingly recognized, suggesting a role for alternative antifungal therapies.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Candida glabratazzm321990; FKS mutation; echinocandin

Year:  2019        PMID： 31345844      PMCID： PMC6658748          DOI： 10.1128/AAC.00512-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Breakthrough invasive candidiasis in patients on micafungin.

Authors:  Christopher D Pfeiffer; Guillermo Garcia-Effron; Aimee K Zaas; John R Perfect; David S Perlin; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

2.  Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates.

Authors:  Mariana Castanheira; Leah N Woosley; Shawn A Messer; Daniel J Diekema; Ronald N Jones; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

3.  Short-course Antibiotic Therapy-Replacing Constantine Units With "Shorter Is Better".

Authors:  Noah Wald-Dickler; Brad Spellberg
Journal:  Clin Infect Dis       Date:  2019-10-15       Impact factor: 9.079

4.  Breakthrough invasive Candida glabrata in patients on micafungin: a novel FKS gene conversion correlated with sequential elevation of MIC.

Authors:  Takeshi Saraya; Koichi Tanabe; Koji Araki; Shota Yonetani; Hiroshi Makino; Takayasu Watanabe; Naoki Tsujimoto; Saori Takata; Daisuke Kurai; Haruyuki Ishii; Yoshitsugu Miyazaki; Hajime Takizawa; Hajime Goto
Journal:  J Clin Microbiol       Date:  2014-04-30       Impact factor: 5.948

5.  Detection of Echinocandin-Resistant Candida glabrata in Blood Cultures Spiked with Different Percentages of FKS2 Mutants.

Authors:  Pilar Escribano; Jesús Guinea; María Ángeles Bordallo-Cardona; Carlos Sánchez-Carrillo; Emilio Bouza; Patricia Muñoz
Journal:  Antimicrob Agents Chemother       Date:  2019-02-26       Impact factor: 5.191

6.  The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Andrea L Kwa; Shaoji Cheng; Chen Du; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

7.  Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.

Authors:  Cau D Pham; Naureen Iqbal; Carol B Bolden; Randall J Kuykendall; Lee H Harrison; Monica M Farley; William Schaffner; Zintars G Beldavs; Tom M Chiller; Benjamin J Park; Angela A Cleveland; Shawn R Lockhart
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

8.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

9.  Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.

Authors:  Guillermo Garcia-Effron; Samuel Lee; Steven Park; John D Cleary; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

10.  In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris.

Authors:  Christopher L Hager; Emily L Larkin; Lisa Long; Fatima Zohra Abidi; Karen J Shaw; Mahmoud A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191
View more
  3 in total

1.  Caenorhabditis elegans as a Model System To Assess Candida glabrata, Candida nivariensis, and Candida bracarensis Virulence and Antifungal Efficacy.

Authors:  Ainara Hernando-Ortiz; Estibaliz Mateo; Marcelo Ortega-Riveros; Iker De-la-Pinta; Guillermo Quindós; Elena Eraso
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

2.  Azole-resistant Aspergillus and Echinocandin-resistant Candida - What are the treatment options?

Authors:  Alison R Novak; Mary E Bradley; Tyree H Kiser; Scott W Mueller
Journal:  Curr Fungal Infect Rep       Date:  2020-03-26

3.  Low level of antifungal resistance of Candida glabrata blood isolates in Turkey: Fluconazole minimum inhibitory concentration and FKS mutations can predict therapeutic failure.

Authors:  Amir Arastehfar; Farnaz Daneshnia; Mohammadreza Salehi; Melike Yaşar; Tuğrul Hoşbul; Macit Ilkit; Weihua Pan; Ferry Hagen; Nazlı Arslan; Hatice Türk-Dağı; Süleyha Hilmioğlu-Polat; David S Perlin; Cornelia Lass-Flörl
Journal:  Mycoses       Date:  2020-08-05       Impact factor: 4.377
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.